+ Watch BMRN
on My Watchlist
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per patient... It goes without saying that Kimberly's math skills are at a preschool level.
I see what they are doing here. Bill Black would be aghast that the same formula for fraud found in the mortgage sector is also found in the biotech sector.The leverage employed in this situation is to sell your product to a non-target patient population that is ' misdiagnosed' by medical practitioners. Soaring national insurance premiums be damned when the risk tables don't match the payouts.Who says you can't sell McMansions to burger flipping high school dropouts at Wendy's...
Have you heard of Alexion (ALXN) and their $400,000 annual charge to each patient with paroxysmal nocturnal hemoglobinuria? How is this possible? Look up FDA orphan drug status. Here are your grades:Math: B+Content knowledge: F-Critical Thinking: DOverall: Needs improvement
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions